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ABSTRACT
Zika virus, a flavivirus like Dengue and West Nile viruses, poses a significant risk 
as a pathogen in the category of emerging infectious diseases. Zika infections typically 
cause nonspecific, mild symptoms, but can also manifest as a neurological disorder 
like Guillain-Barré syndrome. Infection in pregnant women is linked to microcephaly 
in newborn infants. The methyltransferase domain of the non-structural protein 5 
is responsible for two sequential methylations of the 5′-RNA cap. This is crucial for 
genome stability, efficient translation, and escape from the host immune response. 
Here we present the crystal structures of the Zika methyltransferase domain in 
complex with the methyl-donor SAM and its by-product SAH. The methyltransferase-
SAH binary complex presents a new conformation of a “closed” or “obstructed” 
state that would restrict the binding of new RNA for capping. The combination and 
comparison of our new structures with recently published Zika methyltransferase 
structures provide a first glimpse into the structural mechanism of Zika virus mRNA 
capping.
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INTRODUCTION
Zika virus (ZIKV) is a member of Flaviviridae 
family, genus Flavivirus, which includes several mosquito-
borne pathogens, such as Dengue virus (DENV), West 
Nile virus (WNV), Japanese Encephalitis Virus (JEV) and 
Yellow Fever virus (YFV) [1]. First identified in Uganda 
in 1947, the virus received little attention for decades 
until an explosive outbreak in Brazil in 2015 caused by an 
introduction from the Pacific Islands. There are two major 
lineages of the ZIKV: first is the Asian lineage, including 
Southeast Asia, the Pacific region and the Americas. 
Second is the African lineage, including Central, Eastern 
and Western Africa [1, 2]. ZIKV infections in human 
cause nonspecific symptoms like joint pain, mild rash, 
conjunctivitis, but can also manifest as a neurological 
disorder like Guillain-Barré syndrome [3]. Infection in 
pregnant women is linked to microcephaly or other brain 
abnormalities in newborn infants [4–6]. Due to the severity 
of birth defects and the size of the outbreak, the World 
Health Organisation (WHO) declared the virus as a Public 
Health Emergency of International Concern in February 
2016. With no vaccine or approved medication available, 
there remains a pressing need to develop treatment options 
for ZIKV infections.
ZIKV has a ~11 kb single-stranded positive sense 
RNA ((+) ssRNA), which encodes a single 3423 amino 
acid long polyprotein. The polyprotein is further cleaved 
by cellular and viral proteases to yield three structural 
proteins (capsid/C, membrane/prM, and envelope/E which 
form the virus particle and mediate viral encapsidation, 
host attachment and entry) and seven non-structural 
(NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, 
and NS5) which are crucial in viral genome replication, 
evasion from the host immune system and polyprotein 
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processing [1, 7]. Two of these ten proteins, NS3 and 
NS5, have enzymatic activities: NS3 has serine protease, 
RNA triphosphatase (RTPase), nucleoside triphosphatase 
(NTPase), and helicase activities. NS5 shows RNA-
dependent RNA polymerase (RdRp) and methyltransferase 
(MTase) activities [8]. The NS5 methyltransferase domain 
binds GTP and GTP analogues [9–12].
The MTase domain is highly conserved in 
flaviviruses and is responsible for methylation of the 5′-cap 
of the viral genomic RNA. This capping process involves 
four steps [8, 13]: (i) hydrolysis of 5′-triphosphate end 
of the nascent RNA into 5′-diphosphate by RTPase, (ii) 
transfer of GMP from GTP to the 5′-diphosphate by RNA 
guanylyltransferase (GTase), (iii) methylation of N-7 of 
guanine by N-7 MTase yielding m7GpppA-RNA, known 
as cap-0 and (iv) further methylation of the ribose 2′-OH 
position of the first nucleotide of RNA by 2′O MTase, 
yielding m7GpppAm2′O-RNA, also known as the cap-1 
structure. In flaviviruses, the NS5 MTase domain performs 
both N-7 and 2′ -O methylations, using S-adenosyl-l-
methionine (SAM) as a methyl donor and generating 
two S-adenosyl-l-homocysteine (SAH) molecules as 
reaction by-products. A model dubbed the ‘repositioning 
model’ was proposed to describe how flavivirus MTase 
could perform these two methylations: either (i) both 
methylations occur on one MTase molecule, sharing the 
same cofactor-binding site and the RNA substrate must be 
repositioned for the next methylation to take place [13, 14], 
or (ii) methylations involve two MTase molecules, where 
m7GpppA-RNA needs to be dissociated and binds to the 
second MTase molecule for the next methylation to take 
place.  Conceptually, both models imply a series of distinct 
structural conformations along the two methylation 
reactions which should be blatantly different in terms 
of chemistry and catalytic mechanism at the methyl 
acceptor site, ie., one N7-aromatic nitrogen and one 
2′-ribose oxygen. Currently, details of a mechanism for 
2′-O methylation are beginning to emerge. However, those 
of the N7-MTase together with intermediates of loading/
discarding SAM/SAH co-substrates are still elusive. The 
2′-O methylation can occur on short synthetic capped 
RNA oligonucleotides, whereas the N7-MTase requires 
longer authentic sequences [14]. Structural determinants 
promoting the switch between these two activities 
expressed in the MTase domain are still elusive.
RNAs capped by viral MTases cannot be 
distinguished from host mRNAs and as a consequence, 
both are translated into proteins by host ribosomes. 
Uncapped cytoplasmic 5′-triphosphate RNAs are regarded 
as non-self and trigger a host immune response [15–17]. 
The retinoic acid-inducible gene (RIG-1)-like receptors 
(RLRs) recognize uncapped 5′-triphosphate RNA or 
RNA with an incomplete cap and trigger a host immune 
response cascade [18]. Inhibiting the ZIKV MTase may 
suppress viral propagation and hence serve as a potential 
antiviral drug target [19, 20]. The first structures of ZIKV 
MTase and MTase-inhibitor complexes have recently 
been published and initial biochemical experiments 
characterizing the MTase’s activity have been conducted 
[21–23]. 
In this paper, we present two novel crystal 
structures of ZIKV MTase with bound SAM  and SAH, 
which deepen our structural understanding of viral RNA 
capping. The combination of our structures with other 
recently determined ZIKV MTase structures in distinct 
conformational states provides additional insight into 
structural and mechanistic intermediates along the 
sophisticated flavivirus RNA capping pathway. This 
should extend our understanding of the target and aid 
future inhibitor design. 
RESULTS
Protein purification and determination of the 
oligomeric state of ZIKV MTase
The ZIKV MTase was 90% pure as judged by SDS-
PAGE (Figure 1A and 1B). Analytical gel filtration using 
known molecular weight protein standards showed that the 
MTase behaved as a monomer with an apparent molecular 
weight of 30.8 kDa compared to its theoretical monomeric 
molecular weight of 29.4 kDa. (Figure 1C). Although 
ZIKV MTase-SAM and ZIKV MTase-SAH crystals were 
packed as tetramers and dimers respectively, both scored 
low interface areas of 534.4 Å2 and 526.7 Å2 as calculated 
by the COCOMAPS server [24]. The values are lower 
than the average interface areas for homodimers with 
monomeric molecular weight of around 30 kDa, which 
lies around 1800 Å2 [25]. This indicates the oligomers are 
crystallographic and not physiological.
Brief overall description of the two structures
ZIKV MTase is composed of three sub-domains 
(Figure 2A): the major MTase core (residues 54–223) 
contains a Rossmann fold with seven, mixed, β-strands 
(β1 to β7) surrounded by two sets of α-helices (αA, αX 
and αD, αE) on each side. The MTase core provides the 
binding pocket for the methyl donor SAM and after the 
methylation step, it houses the by-product SAH. It also 
contains the catalytic tetrad motif Lys61-Asp146-Lys182-
Glu218 shown to be involved in 2′O methylations to 
generate the cap-1 structure [26]. The small consensus 
motif 1 Gly-x-Gly-x-Gly-x, in our case GC-GR-GG 
(residues 81 to 86) is considered to be the hallmark of 
the SAM-binding site in the Rossmann fold for SAM-
dependent methyltransferases [12, 27, 28]. The MTase 
core sub-domain is flanked by two smaller sub-domains 
termed the N-terminal and C-terminal extensions. Both 
are located on the same side of the core sub-domain and 
provide additional helical secondary elements (A1 to A4). 
Although all published ZIKV MTase structures originate 
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from Asian ZIKV genotypes [2], sequences for 5KQR, 
5KQS and 5M5B were from French Polynesia [21] and 
5GP1 and 5GOZ were isolated from Hangzhou, China 
[29]. Our MTase sequence is based on an isolate from 
Guangdong, China and is mutated in two positions, E67D 
and M114V (Figure 2B). E67D is located at the end of 
helix αX and is solvent-exposed. Although helix αX is 
important for cofactor binding through residues Lys61, the 
mutated residue does not contribute to cofactor binding 
and faces in the opposite direction. The second mutation, 
M114V, is located in a predominantly hydrophobic pocket 
involving Val55, Leu44 and Val116 and fits snugly into 
the surrounding environment. This region is a part of 
the putative RNA binding pocket but whether or not this 
residue contributes to RNA binding is unknown. 
Description of ZIKV MTase in complex with SAM 
Recently a series of ZIKV MTase-SAM complexes 
have been described [7, 21, 30, 31], therefore, we will only 
briefly explain our structure obtained with a new crystal 
form (see Methods, and Table 1). The cofactor SAM is 
bound in the central cleft formed of β-strands β1, β2, β4 
and helices αX and αA (Figure 2A). The electron density 
of the Fo-Fc map contoured at 3σ for SAM is shown in 
Figure 2E. SAM predominantly sits in the hydrophobic 
pocket with several notable hydrogen bond interactions. 
The adenine base of SAM forms H-bond interactions 
with the main chain oxygen of Asp131. The main chain 
nitrogen atoms of Lys105 and Val132 also form H-bond 
interactions with the nitrogen in the ring system of the 
adenine base. On the other hand, the methionine of the 
SAM forms H-bond interactions with the side-chains of 
Ser56, Trp87 and Asp146, as well as with the main-chain 
nitrogen of Gly86. The interactions between SAM and the 
residues are shown as a Ligplot interaction in Figure 2C 
[32]. SAM has the same conformation and interactions 
in all four molecules of the asymmetric unit (AU) and 
together with the other molecules (molecule A in PDB ID 
5M5B, and 5KQR; molecules A to H in 5WZ1) provides 
independent structural evidence of functional interactions 
of the cofactor with ZIKV MTase, independently of 
Figure 1: Bar diagram of ZIKV NS5 protein and purification of its MTase domain for structural studies. (A) Bar diagram 
of non-structural protein 5 from ZIKV virus. The entire protein consists of 903 residues comprising an N-terminal MTase domain connected 
by a linker region to a C-terminal RdRp domain. The MTase domain includes the core domain (dark blue), which includes the cofactor, GTP 
and RNA binding pockets, and if flanked by smaller N-terminal (light blue) and C-terminal (light green) subdomains. (B) SDS-PAGE gel 
showing the purity of ZIKV MTase used for crystallization. (C) Determination of the oligomeric state of ZIKV MTase using gel filtration 
chromatography. Calibration curve for the estimation of the molecular weight where the y-axis represents the log of molecular weight of the 
protein standards (●) and ZIKV MTase (▲) versus their individual Kav calculated from gel filtration experiments.
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the crystal form. It is also noteworthy that in two of the 
molecules, residues Ala43 to Glu46 (molecule C) and 
Leu44 to Val48 (molecule D) are missing, an indication 
of intrinsic flexibility in this region of the protein, the 
importance of which will be discussed later.     
Description of ZIKV MTase in complex with SAH 
Our second, new crystal form (Table 1) reveals 
the structure of ZIKV MTase in complex with the by-
product SAH. It contains two molecules in the AU. SAH 
is still bound in the SAM binding pocket and therefore 
represents a conformation after transfer of the methyl 
group. (Figure 2D). The electron density of the Fo–Fc 
map at 3σ for the by-product SAH delineates the cofactor 
without the methyl group, clearly visible at this resolution 
(Figure 2F). SAH, like SAM, predominantly sits in the 
hydrophobic pocket with several notable hydrogen bond 
interactions. Overall, SAM and SAH show the same 
interactions with protein residues of the binding pocket as 
seen earlier for methyltransferases from other flaviviruses 
[33]. The adenine base of SAH forms H-bond interactions 
with Lys105, Asp131 and Val132. H-bond interactions 
with side-chains Ser56, Trp87, Asp146 and Gly86 with 
the SAH methionine tail are similar to those observed 
in SAM. In addition, the two molecules in the AU have 
identical interactions in the SAH binding region and there 
are no significant variations in the binding of the by-
product, although minor changes occur due to differences 
in the quality of the map between protein chains. However, 
there are major structural differences between these two 
molecules in the AU, the functional importance of which 
will be discussed later.
Description of the cap-binding pocket 
We did not use GTP, non-methylated or methylated 
RNA cap analogues before or during crystallization. As 
expected the cap-binding pocket is empty in both of our 
SAM- and SAH-bound structures. Upon comparison of 
Figure 2: Overall description of the MTase domain with bound SAM or SAH. (A) ZIKV MTase domain showing the 
overlay of the cofactors SAM and SAH shown in ball-and-stick representation. The structure consists of three subdomains: the N-terminal 
extension (colored in blue), the MTase core domain (shaded in wheat) containing the cofactor binding pocket and the tetrad motif (shown as 
red spheres) and the C-terminal subdomain (colored in yellow). (B) Mutations E67D and M114V in our structure overlaid with previously 
published structures show that they do not cause any conformational changes. Ligplot [32] presentation of the (C) SAM-binding and 
(D) SAH-binding pockets. Dashed green lines indicate hydrogen bonds, and the half-moon represents hydrophobic interactions between 
residues of the protein and the cofactor or byproduct, respectively. The electron-density of the cofactors Fo–Fc difference electron density 
(contoured at 3σ) for (E) SAM and (F) SAH is shown as a blue mesh. 
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our structures with ZIKV MTase structures with bound 
GTP, N7MeGpp or N7Me-Gppp there are no major differences 
between GTP or cap-analogue bound complexes and our 
“empty” cap-binding pockets. Interestingly, Phe24 (Phe25 
in DENV) that is important for a stacking interaction with 
the guanine moiety of the cap 0 RNA still has the same 
orientation in our structure (Supplementary Figure 2).  
Evidence for structural changes in the putative RNA 
binding pocket of the SAH-bound structure 
Although the two molecules in the AU both represent 
the MTase-SAH binary complex, they display significant 
structural changes outside the cofactor and cap-binding 
pockets, close to the putative RNA binding region. The short 
loop L3 and helix A3 are considered to be part of the putative 
RNA binding pocket. In chain B, spanning residues Glu38 to 
Gly52 (Supplementary Figure 1A, 1C), there is no electron 
density in this region and this part of the model is entirely 
absent, indicating its intrinsic flexibility. Surprisingly, in 
molecule A of our SAH bound structure we observed that this 
region is present, albeit in an entirely novel conformation, 
which we term the “closed” conformation (Figure 3A, 3B).
DISCUSSION 
Several viral pathogens of the flavivirus family such 
as DENV and ZIKV are the causing agents of a variety of 
diseases. Non-structural protein 5 with its two major protein 
domains, the RdRp and the MTase domains, is of particular 
Table 1: Data collection, data processing, structure determination and refinement statistics for two new crystal forms 
of ZIKV MTase
Binary MTase-SAM complex Binary MTase-SAH complex
Data Collection
Wavelength (Å) 0.9795 0.9163
Resolution range 54.53–2.0 (2.072–2.0) 39.01–2.10 (2.21–2.10)
Space group P61 P43212
Unit cell (a, b, c, α, β, γ) 125.9,125.9, 125.9, 90, 90, 120 67.4, 67.4, 272.6, 90, 90, 90
Total reflections 603 237 (84 193) 291 550 (45 016)
Unique reflections 76 301 (11 052) 37 913 (5 414)
Multiplicity 7.9 (7.6) 7.7 (8.3)
Completeness (%) 100.0 (100.0) 99.8 (100.00)
Mean I/σ (I) 15.8 (2.4) 13.4 (3.2)
R
merge 8.2 (63) 11.1 (68)
Half-set correlation CC (1/2) 72.6 (26.8) 91.7 (28.9)
Refinement










R.m.s.d., bonds 0.012 0.012
R.m.s.d., angles 1.46 1.25
Ramachandran plot
..Favored (%) 97.1 97.7
..Allowed (%) 2.6 1.9
..Outliers (%) 0.3 0.4
Bound Ligand SAM SAH
Statistics for the highest-resolution shell are shown in parentheses.
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interest. Their functions are essential for viral propagation 
and dissecting their detailed molecular mechanism is not 
only interesting from a fundamental point of view, but 
may also help to ultimately develop compounds targeting 
NS5. Revealing novel conformations in both domains 
may ultimately lead to the identification of novel inhibitor 
binding pockets, in particular for conformational states, 
which have not been revealed yet. Both RdRp and MTase 
domains are targets for small molecule development in both 
DENV and ZIKV and small molecule and fragment hits are 
now appearing in the literature, often from DENV or HCV-
derived inhibitors, for both RdRp and MTase domains [19, 
20, 22, 23, 34, 35].
The ZIKV MTase-SAH complex is in a “closed” 
RNA-obstructive conformation 
To assess the potential functional significance of our 
new conformation observed in the MTase-SAH complex 
we superimposed and compared it with the MTase-SAM 
complex (PDB ID 5KQR) (Figure 3A). We identified a 
significant conformational change in the loop L3 / helix 
A3 region, a region which is well known from previous 
structures and our MTase-SAM complex to display 
intrinsic flexibility. Whereas in the MTase-SAM complex 
this region is in an “open” or “permissive” conformation 
(Figure 3A, magenta colour), in our new MTase-SAH 
complex the onset of the A3 region has moved by about 
6 Å towards the putative RNA binding region and is now 
in the “closed” or “obstructive” position (Figure 3A, 
cyan colour). In this “closed” orientation, A3 is one turn 
shorter than A3 in the “open” position. We can rule out 
a crystallographic artefact, as there are no residues of 
symmetry related molecules interacting with this region, 
which would impose such a conformation. The functional 
relevance becomes more obvious when we overlay 
our new MTase-SAH structure with the ternary DENV 
MTase complex in complex with SAH and m7Gppp-RNA 
([36] (PDB ID: 5DTO). ZIKV and DENV serotype 3 
share 63.4% sequence identity in the MTase domain 
(12.3% strong similarity; 8.6% weak similarity; 15.7% 
different). The ZIKV MTase sequence only displays two 
minor amino acids insertions in loop regions compared 
to DENV serotype 3 MTase. The overlay between ZIKV 
and DENV MTase-SAM complex structures display 
an r.m.s. deviation of 0.5, indicating the high sequence 
and structural similarity between these two proteins. On 
superimposition, the loop L3 / helix A3 region of the 
DENV MTase-SAH-cap 0 RNA complex is clearly in the 
“permissive” orientation, with the m7GPP-RNA occupying 
the RNA binding region between the gatekeeper region 
and helix A2 (Figure 3B, green colour). On the contrary, 
in our structure, the loop L3 / helix A3 region has moved 
towards the putative RNA binding region and residues of 
this region would clash with the RNA. It should be noted 
that in all other ZIKV structures and all other flavivirus 
MTase-SAH complexes (Supplementary Table 1 of the 
supplementary material section) presently available, 
the loop L3 / helix A3 region is either flexible or in the 
“open” position. We hypothesize that our ZIKV MTase 
structure represents a novel conformation, in which, after 
the RNA cap has been methylated, the by-product SAH 
is still bound in the cofactor-binding pocket, but the A3 
region inhibits further binding of a new mRNA by being 
in an “obstructive” orientation. We call this region the 
Figure 3: Identification of a “closed” conformation of the RNA binding cleft in the SAH-bound MTase structure. 
(A) Overlay of chain A of our SAH-bound structure (cyan) with a SAM-bound structure (PDB ID: 5KQR, magenta) depicting the major 
conformational change in the loop L3 / helix A3 region. (B) Overlay of our “closed” conformation structure (L3 and A3 are coloured in 
cyan) with the MTase-m7GpppG-RNA binary complex (respective regions shaded in green) of the DENV serotype 3 structure (PDB ID: 
5DTO [36]),  showing the “open” and “closed” conformation of the RNA binding groove. Please note that the “closed” conformation would 
significantly restrict the space available for the RNA.
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gatekeeper, because it controls binding of new mRNA to 
MTase.
A structural model for the mechanism of mRNA 
capping in ZIKV virus 
Based on recently published and our new ZIKV 
MTase structures we can now propose an initial structural 
model for the mechanism of mRNA capping in Zika virus 
(Figure 4) in analogy to other flaviviruses such as DENV 
or WNV [8, 11, 14, 37]. There are some limitations to the 
model: our model concentrates on structural changes in the 
MTase domain, which is part of the larger NS5 protein that 
also contains the RdRp domain. Major structural changes, 
in particular domain movements in the full-length NS5 
protein induced by different cofactors or mRNA cap 
analogues are not captured in our model. Generally, short 
cap analogues but not cap-RNA moieties are used for the 
generation of MTase-cap complexes, but this is a general 
limitation for flavivirus research. However, since all of 
the MTase structures have been solved at high resolution, 
we are able to capture subtle changes, which would not 
easily be detected in the lower resolution full-length NS5 
structures [38, 39]. 
(i) The apo-state of ZIKV MTase without cofactor 
or bound RNA is represented by molecule B of PDB ID 
5M5B. In this structure the loop L3 / helix A3 region is in 
the permissive orientation. (ii) SAM, the cofactor required 
for the first methylation step, binds to its designated 
binding site. This state is represented by PDB ID 5KQR, 
molecule A, molecules A-H of 5WZ1 and our new 
structure (PDB ID 5NJV) with four molecules in the AU. 
(iii) The viral RNA destined for N7 guanine methylation 
is recognized by the MTase and binds to its binding 
pocket. Unfortunately, no crystal structure is available 
for this ternary complex. It is possible that the gatekeeper 
region could be in the “obstructive” conformation, since 
the binding mode of RNA at this stage is not known. 
The gatekeeper precludes binding for a 2′-O methylation 
competent state, but we do not know if the “obstructive” 
Figure 4: Proposed model of ZIKV MTase structure and function. The 5′ end of flavivirus RNA such as ZIKV is modified 
by the addition of a cap structure. This cap is subsequently methylated at the N7 position of the guanosine (cap-0) and at the 2′-hydroxyl 
group of the following nucleotide (cap-1). Both methylations are catalyzed by the same enzyme, MTase. Numbers (i) to (viii) represent the 
individual steps of the capping mechanism either by the one MTase molecule or by the two MTase model. (ix) represents the new RNA 
obstructive stage revealed by our novel closed conformation SAH-bound structure. The surface representation of the MTase domain is 
shown in light grey in the one MTase model and changes to light blue in the two MTase model. The cofactors SAM and its by-product SAH 
are coloured in red and blue, respectively. The blue-coloured tube represents the gatekeeper loop L3/helix A3 region in either its permissive 
or flexible, unstructured conformation, whereas its obstructive conformation is shown in purple colour. The uncapped and capped mRNA 
is shown in black and green. Potential conformational states for which structures have been published are indicated with their PDB IDs 
(orange), whereas missing conformational states are indicated by a red asterix.
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conformation could actually accommodate an RNA 
molecule ready to be methylated at the cap-guanine N7-
position. So far it is not known yet whether SAM has 
to bind first, before the RNA can subsequently bind or 
whether SAM can bind after recruitment of the RNA. (iv) 
Subsequently, the methyl group from SAM is transferred 
to the N7 of guanine of the RNA resulting in the capping 
of the first site and the simultaneous generation of SAH 
as the by-product, which contains bound SAH and the 
capping analogue 7MeGpppA. A structure of this stage is 
not available. 
For flaviviruses, two putative models have been 
proposed for the second step of cap methylation, 
either the one MTase model, or the two MTase model 
[10, 40]. In the model involving a single MTase domain 
that performs both N-7 and 2′-O methylations, the by-
product SAH is replenished with SAM. For this step to 
occur, SAH has to leave the binding pocket (vA), SAM 
as the methyl group provider for the second methylation 
has to bind and the mRNA has to be repositioned (vi) so 
that its 7MeG moiety binds to the GTP binding pocket and 
that the 2′-OH of the adenine ribose is in proximity to 
SAM for the second methylation step for mRNA capping 
[8, 13]. If the gatekeeper was closed, it has to switch to 
the “open” position. It is not known for any flavivirus 
if RNA repositioning occurs before or after binding of 
SAM. No crystal structure is available for the binary 
complex of ZIKV MTase in complex with 7MeGpppAG-
RNA (or one of its capping analogues), but in the 
absence of SAM, there is the ternary complex of MTase 
in complex with SAM and a very short cap analogue 
7MeGpp, represented by PDB ID 5KQS. Subsequently, a 
second methyl group is donated by SAM leading to the 
aforementioned cap-1 structure with methylation at the 
2′-O position (vii), resulting in the generation of SAH as 
a by-product. For this complex, a structure is available 
for DENV [36]. Since the methylated viral RNA cap 
is not distinguishable from a normal host cap structure 
anymore, thus avoiding recognition by the host system, 
the capped RNA is released from the MTase (viii) 
resulting in a binary MTase-SAH complex, represented 
by molecule B of 5NJU and molecule A of 5WXB. 
Finally, the gatekeeper region changes its conformation 
from the “permissive” to its “obstructive” conformation 
(ix), restricting the binding of new uncapped RNA to the 
MTase domain (molecule A of 5NJU). It is not yet known 
whether SAH is recycled to SAM and whether NS5 is 
recycled or degraded.
In the model involving two distinct MTase 
domains, the N-7 methylated cap-RNA is transferred and 
correctly repositioned to a second MTase domain (vB) 
and the subsequent methylation at the 2′-O position then 
follows the same mechanism as described for the one 
MTase model. Currently it is not known, which of the 
two models is correct. Radioactive enzymatic assays of 
ZIKV MTase in the presence of various 5′-end modified 
synthetic RNAs confirmed that the domain possesses 
N7 and 2′O methyltransferase activities, similar to other 
flavivirus MTases [22]. More structural, biochemical 
and biophysical work is needed to better understand the 
mechanism of capping of ZIKV mRNA but knowledge 
gained from other important flaviviruses such as DENV 
or WNV will guide future structural work for this 
emerging virus.
MATERIALS AND METHODS
Cloning, expression and purification of ZIKV 
MTase
The DNA insert codon-optimised for expression in 
Escherichia coli encoding the 264 amino acids of ZIKV 
MTase (genebank accession AMR39831.1) in pSUMO2 
expression vector was ordered from GenScript. The 
construct had an N-terminal octahistidine affinity tag and 
a small ubiquitin-like modifier (SUMO) tag with a Ulp1 
protease cleavage site. The plasmid was transformed into 
E. coli BL21 (DE3) Rosetta expression cells (Novagen) 
and grown in 6 L of culture in Terrific Broth medium 
at 37° C supplemented with 34 μg/ml chloramphenicol 
and 50 μg/ml kanamycin to A600 of 1–1.2 (16–18 h). The 
cultures were then induced for protein expression with 
0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 
24 h at 20° C. The cells were subsequently harvested by 
centrifugation for 10 min at 8000 rpm, 4° C and stored at 
–80° C.
The purification procedure for ZIKV MTase 
was similar to a previously published one [21] with 
some modifications. Cells were lysed by sonication 
(16m amplitude, 4° C, 10 cycles of 30 sec ON and 
60 sec OFF) after resuspending in buffer A (50 mM 
2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonic acid 
(HEPES), pH 7.2, 500 mM NaCl, 5% glycerol and 5 mM 
β-Me) supplemented with 1 mM phenylmethylsulfonyl 
fluoride (PMSF). The lysate was then cleared by 
centrifugation at 20,000 rpm for 1 h at 4° C and then loaded 
onto a 5 mL HisTrap FF column (GE Healthcare) pre-
equilibrated with buffer A. The column was then washed for 
50 column volumes (CV) with buffer A supplemented with 
25 mM imidazole. Finally, the bound protein was eluted 
on a gradient of buffer A from 25 to 250 mM imidazole for 
20 CV and collected as 2 ml fractions in a 96-well block. 
The fractions containing the MTase protein were pooled 
for subsequent steps. Dialysis using SnakeSkin™ dialysis 
membrane with 10 kDa MWCO (molecular weight cut off) 
(Thermo Fisher Scientific) and cleavage of the His-SUMO 
tag by Ulp1 protease (ratio protease to protein of 1:100) 
for 16–18 h at 4° C were performed simultaneously on the 
pooled protein. Dialysis buffer D contained 50 mM HEPES 
pH 7.5, 500 mM NaCl, 5% glycerol and 5 mM β-Me. The 
cleaved protein was then loaded onto a 5 mL HisTrap FF 
column pre-equilibrated with buffer D and the unbound 
Oncotarget3168www.impactjournals.com/oncotarget
cleaved protein containing flow-through was collected as 
2 ml fractions. 
The cleaved protein was then diluted 10-fold in ion 
exchange buffer E (50 mM HEPES pH 7.5, 5% glycerol 
and 5 mM β-Me) to reduce the NaCl concentration from 
500 mM to 50 mM, and loaded on a 5 mL cation exchange 
HiTrap SP FF column (GE Healthcare). The column was 
washed for 10 CV with buffer E and the protein was eluted 
using gradient elution of ion exchange buffer from 0 to 1 
M NaCl. The protein was further purified by size exclusion 
chromatography using a XK 16/100 Superose 12 column 
(GE Healthcare) in gel filtration buffer F (50 mM HEPES 
pH 7.5, 400 mM NaCl 5% glycerol, 2 mM β-Me). The 
protein fractions were pooled and concentrated to 
10 mg/mL using a Amicon® Ultracel 10 MWCO 
concentrator. The protein was frozen in liquid nitrogen 
and stored at –80° C. 
Crystallization of ZIKV MTase
Crystallization screens were set up using various 
commercial screens. Crystals for ZIKV MTase appeared 
after 5–7 days in 0.1 M citric acid pH 5.0 and 2 M 
NaCl at 18° C. The crystals were further optimized by 
streak seeding to obtain single crystals for diffraction 
measurements. In addition, reproduction of the ZIKV 
MTase crystals from the first published condition [21] was 
also carried out. The crystals grew in 0.1 M Tris pH 7.0 
and 21% PEG 400 at 18° C. However, crystals grew in 
a new crystal form. Neither SAM nor SAH were added 
during the purification procedure or during crystallization 
and therefore originate from E. coli.
Analysis of the oligomeric state using gel 
filtration
Gel filtration analysis of the MTase domain was 
performed to determine the oligomeric state of the protein 
(XK 16/100 Superose 12 column (GE Healthcare); 50 mM 
HEPES pH 7.5, 400 mM NaCl 5% glycerol and 2 mM 
β-Me). Experiments were conducted using a flow rate of 1 
ml/min and an injection volume of 1 ml. Prior to running 
the MTase, the column was calibrated with proteins 
of known molecular mass (ribonuclease A: 13.7 kDa; 
ovalbumin: 43 kDa; albumin: 66 kDa; aldolase: 150 kDa; 
ferritin: 440 kDa; Blue Dextran 2000, >2000 kDa). The 
Kav values were calculated for these calibration proteins 
[(Ve - Vo)/(Vc - Vo)], where Ve is the elution volume, Vo is 
the void volume and Vc is the column volume and the Kav 
values were then plotted against the log of the molecular 
weights of the standards. The molecular mass of ZIKV 
MTase was calculated from the resulting equation and 
subsequently used to determine the oligomeric state of the 
protein. Protein-protein interface areas for each molecule 
in the crystal packing were calculated using COCOMAPS/
bioCOmplexes Contact MAPS [24] by uploading the 
coordinate files to the server.
Data collection, structure determination and 
refinement
ZIKV MTase crystals grown in 0.1 M citric acid pH 
5.0 and 2.0 M NaCl on a 1:1 ratio of protein and reservoir 
solution in hanging drops were cryo-protected (15% w/v 
glycerol in 1.2 fold of reservoir solution) and flash-frozen 
in liquid nitrogen. The reproduced crystals grown in 0.1 
M Tris pH 7.0 and 21% PEG 400 were cryo-protected 
in 1.2 fold of reservoir solution containing 9% sucrose, 
2% glucose, 8% glycerol and 8% ethylene glycol, as 
previously described [21].
Diffraction data for individual crystals were 
collected at beamlines I04 and I04-1 at Diamond Light 
Source. Data were processed using either XDS [41] or 
iMosflm [42] and scaled to resolutions as mentioned in 
Table 1 [43]. The structures of ZIKV MTase were solved 
by molecular replacement (PHASER MR in CCP4 
suite) using ZIKV MTase (PDB code 5GOZ,[29]) as a 
search model. All structures were initially refined with 
REFMAC5 [44]. Electron density and difference density 
maps, all σA-weighted, were inspected, and the models 
were improved using Coot [45]. Further refinement of 
the structures was performed using PHENIX [46]. The 
calculation of Rfree used 5% of data. Crystallographic and 
refinement statistics are given in Table 1.
Crystals of the binary MTase-SAM complex 
contain four molecules in the AU. Molecule A covers 
residues Thr4 to Arg264, molecule B contains residues 
Thr4 to Ala265, molecule C includes residues Gly5 to 
Arg42 and Gly47 to Arg264, and molecule D covers 
residues Thr4 to Ala43 and Ala49 to Arg264. All 
molecules contain the cofactor SAM. Chain C and 
Chain D have disordered regions of Ala43 to Asp46 and 
Leu44 to Val48, respectively. The second crystal form 
containing the binary MTase-SAH complex (one SAH 
/ molecule) contains two molecules in the AU. Whereas 
molecule A includes residues Gly5 to Arg264, molecule 
B covers residues Gly5 to Arg37 and Val53 to Arg264. 
The missing region Glu38 to Gly52 is known to be part 
of the putative RNA binding pocket. 
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